<DOC>
	<DOC>NCT00863174</DOC>
	<brief_summary>Safety and bioequivalence of SPARC_147709</brief_summary>
	<brief_title>A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Availability for the entire study period and willingness to adhere to protocol requirements. Diagnosis of multiple myeloma and eligible for receiving Doxorubicin liposome 18 years of age or older No evidence of underlying disease (except multiple myeloma) History or presence of significant allergy or significant history of hypersensitivity or idiosyncratic reactions to doxorubicin hydrochloride History of cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic,dermatologic, musculoskeletal, neurological or psychiatric disease. History of smoking (≥ 10 cigarettes/day) or consumption of tobacco products (≥ 4 chews/day). Positive result to HIV, HCV, RPR and HBsAg.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bio-equivalence</keyword>
</DOC>